With Lilly JAK Tie-up, Incyte Aims To Chase Pfizer In Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
No time to lose: A deal for an earlier-stage oral drug underscores Big Pharma's passion for new targets in inflammatory diseases.